Drug Profile
Monoclonal antibody cytokine fusion protein therapeutic - Horizon Therapeutics plc
Latest Information Update: 06 Nov 2023
Price :
$50
*
At a glance
- Originator Viela Bio
- Developer Horizon Therapeutics plc
- Class Anti-inflammatories; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation